<DOC>
	<DOCNO>NCT02920229</DOCNO>
	<brief_summary>Single-center , prospective , diagnostic trial radically treat patient biochemical recurrence prostate cancer . Patients radically treat prostate cancer biochemical relapse negativity traditional morphological functional imaging ( transrectal ultrasound , bone scan , 18F-FMC PET/CT , CT/MRI ) doubtful image 2-deoxy-2- [ fluorine-18 ] ( 18F ) -fluoromethylcholine ( FMC ) PET/CT receive Gallio-68 ( 68Ga ) - Prostate Specific Membrane Antigen ( PSMA ) Positron Emission Tomography ( PET ) /Computed Tomography ( CT ) scan .</brief_summary>
	<brief_title>68Ga-PSMA HBED-PET/CT Evaluation Biochemical Relapse Patients With History Prostate Cancer Radically Treated</brief_title>
	<detailed_description>Single-center , prospective , diagnostic trial . The primary objective study evaluate sensitivity 68Ga-PSMA PET /CT define ratio number 68Ga-PSMA PET /CT positive patient number prostate cancer patient biochemical relapse negative standard imaging . The secondary objective : - Sensitivity different Prostatic Specific Antigen ( PSA ) value ( range ) - Sensitivity different lesion sit - Treatment response assessment second PET - False positive detection Follow Up ( FUP ) ( standard method eventually optional biopsy ) patient without treatment - safety 67 evaluable patient inject 100-200 megabecquerel ( MBq ) 68Ga-PSMA intravenously</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm prostate cancer 2 . Male , age &gt; 18 year . 3 . Radical treatment prostate cancer ( radiotherapy surgery ) 4 . 18FFMC PET/CT negative doubtful 5 . Negativity traditional morphological functional imaging ( transrectal ultrasound , bone scan , CT/MRI ) 6 . Patients PSA progression define PSA â‰¥ 1,0 ng/mL and/or PSA rise define 2 subsequent value show PSA increase least 1 week apart . 7 . Male participant whose partner child bear potential must willing ensure partner use effective contraception study 3 month thereafter 8 . Participant willing able give inform consent participation study . 1 . No hormonotherapy last 6 month 2 . No radiotherapy last 6 month . 3 . Patients PSA &lt; 1.0 ng/ml 4 . Participation another clinical trial investigational agent within 30 day prior study screen . 5 . History allergic reaction attribute compound similar chemical biologic composition Study Agent . 6 . Medical psychological condition would permit subject complete sign inform consent</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>68Ga-PSMA</keyword>
	<keyword>HBED-PET/CT</keyword>
	<keyword>biochemical relapse</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>radically treat</keyword>
</DOC>